Login to Your Account



Palleon lands $47.6M Series A round to target glycoimmune checkpoints

By Brian Orelli
Staff Writer

Wednesday, October 4, 2017

T-cell checkpoint inhibitors, such as drugs targeting PD-1/PD-L1 and CTLA-4, have been successful at helping the immune system attack certain tumors, but the drugs fail to spur a response in many tumor types.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription